Maximizing CD8+ T Cell Responses Elicited by Peptide Vaccines Containing CpG Oligodeoxynucleotides

Overview

Journal Clin Immunol

Specialty Allergy & Immunology

Date 2007 Jun 23

PMID 17584532

Citations 9

Authors

James N Kochenderfer

Christopher D Chien

Jessica L Simpson

Ronald E Gress

Affiliations

Soon will be listed here.

Abstract

We assessed the ability of several factors to increase the size of tumor-antigen-specific CD8(+) T cell responses elicited by vaccines incorporating peptides and CpG-containing oligodeoxynucleotides (CpG). Neither granulocyte-macrophage colony-stimulating factor (GM-CSF) nor an immunogenic MHC class II-presented "helper" peptide increased the size of epitope-specific CD8+ T cell responses elicited by peptide+CpG-containing vaccines. In contrast, low-dose subcutaneous interleukin (IL)-2 dramatically increased the size of splenic and peripheral blood epitope-specific CD8(+) T cell responses generated by peptide+CpG-containing vaccines. Moreover, peptide+CpG-containing vaccines plus low-dose IL-2 mediated anti-tumor immunity. A prime-boost vaccination schedule elicited larger CD8(+) T cell responses than a weekly vaccination schedule. Including larger doses of peptide in vaccines led to larger vaccine-elicited CD8(+) T cell responses. Clinical trials of CpG-containing peptide vaccines are ongoing. These findings suggest strategies to increase the size of CD8(+) T cell responses generated by CpG-containing peptide vaccines that could be tested in future clinical trials.

Citing Articles

Constant regulation for stable CD8 T-cell functional avidity and its possible implications for cancer immunotherapy.

Gilfillan C, Hebeisen M, Rufer N, Speiser D Eur J Immunol. 2021; 51(6):1348-1360.

PMID: 33704770 PMC: 8252569. DOI: 10.1002/eji.202049016.

Co-delivery of human cancer-testis antigens with adjuvant in protein nanoparticles induces higher cell-mediated immune responses.

Neek M, Tucker J, Kim T, Molino N, Nelson E, Wang S Biomaterials. 2017; 156:194-203.

PMID: 29202325 PMC: 5783197. DOI: 10.1016/j.biomaterials.2017.11.022.

Improving Multi-Epitope Long Peptide Vaccine Potency by Using a Strategy that Enhances CD4+ T Help in BALB/c Mice.

Ghaffari-Nazari H, Tavakkol-Afshari J, Jaafari M, Tahaghoghi-Hajghorbani S, Masoumi E, Jalali S PLoS One. 2015; 10(11):e0142563.

PMID: 26556756 PMC: 4640540. DOI: 10.1371/journal.pone.0142563.

Peptide Dose and/or Structure in Vaccines as a Determinant of T Cell Responses.

Leggatt G Vaccines (Basel). 2015; 2(3):537-48.

PMID: 26344744 PMC: 4494221. DOI: 10.3390/vaccines2030537.

Enhanced cytotoxicity and decreased CD8 dependence of human cancer-specific cytotoxic T lymphocytes after vaccination with low peptide dose.

Lovgren T, Baumgaertner P, Wieckowski S, Devevre E, Guillaume P, Luescher I Cancer Immunol Immunother. 2011; 61(6):817-26.

PMID: 22080404 PMC: 11029156. DOI: 10.1007/s00262-011-1140-1.

References

Sandler A, Chihara H, Kobayashi G, Zhu X, Miller M, Scott D . CpG oligonucleotides enhance the tumor antigen-specific immune response of a granulocyte macrophage colony-stimulating factor-based vaccine strategy in neuroblastoma. Cancer Res. 2003; 63(2):394-9. View

Weber J, Sondak V, Scotland R, Phillip R, Wang F, Rubio V . Granulocyte-macrophage-colony-stimulating factor added to a multipeptide vaccine for resected Stage II melanoma. Cancer. 2002; 97(1):186-200. DOI: 10.1002/cncr.11045. View

Blattman J, Grayson J, Wherry E, Kaech S, Smith K, Ahmed R . Therapeutic use of IL-2 to enhance antiviral T-cell responses in vivo. Nat Med. 2003; 9(5):540-7. DOI: 10.1038/nm866. View

Davila E, Kennedy R, Celis E . Generation of antitumor immunity by cytotoxic T lymphocyte epitope peptide vaccination, CpG-oligodeoxynucleotide adjuvant, and CTLA-4 blockade. Cancer Res. 2003; 63(12):3281-8. View

Yang J, Sherry R, Steinberg S, Topalian S, Schwartzentruber D, Hwu P . Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer. J Clin Oncol. 2003; 21(16):3127-32. PMC: 2275327. DOI: 10.1200/JCO.2003.02.122. View

Overwijk W, Theoret M, Finkelstein S, Surman D, de Jong L, Vyth-Dreese F . Tumor regression and autoimmunity after reversal of a functionally tolerant state of self-reactive CD8+ T cells. J Exp Med. 2003; 198(4):569-80. PMC: 2194177. DOI: 10.1084/jem.20030590. View

Yang Y, Huang C, Huang X, Pardoll D . Persistent Toll-like receptor signals are required for reversal of regulatory T cell-mediated CD8 tolerance. Nat Immunol. 2004; 5(5):508-15. DOI: 10.1038/ni1059. View

Rosenberg S, Yang J, Restifo N . Cancer immunotherapy: moving beyond current vaccines. Nat Med. 2004; 10(9):909-15. PMC: 1435696. DOI: 10.1038/nm1100. View

Bloom M, Robbins P, Li Y, Rosenberg S, Yang J . Identification of tyrosinase-related protein 2 as a tumor rejection antigen for the B16 melanoma. J Exp Med. 1997; 185(3):453-9. PMC: 2196033. DOI: 10.1084/jem.185.3.453. View

10.

Ahlers J, Dunlop N, Alling D, Nara P, Berzofsky J . Cytokine-in-adjuvant steering of the immune response phenotype to HIV-1 vaccine constructs: granulocyte-macrophage colony-stimulating factor and TNF-alpha synergize with IL-12 to enhance induction of cytotoxic T lymphocytes. J Immunol. 1997; 158(8):3947-58. View

11.

Ridge J, Rosa F, Matzinger P . A conditioned dendritic cell can be a temporal bridge between a CD4+ T-helper and a T-killer cell. Nature. 1998; 393(6684):474-8. DOI: 10.1038/30989. View

12.

Bronte V, Chappell D, Apolloni E, Cabrelle A, Wang M, Hwu P . Unopposed production of granulocyte-macrophage colony-stimulating factor by tumors inhibits CD8+ T cell responses by dysregulating antigen-presenting cell maturation. J Immunol. 1999; 162(10):5728-37. PMC: 2228333. View

13.

Rosenberg S, Yang J, Schwartzentruber D, Hwu P, Marincola F, Topalian S . Impact of cytokine administration on the generation of antitumor reactivity in patients with metastatic melanoma receiving a peptide vaccine. J Immunol. 1999; 163(3):1690-5. PMC: 2249693. View

14.

Wherry E, Puorro K, Porgador A, Eisenlohr L . The induction of virus-specific CTL as a function of increasing epitope expression: responses rise steadily until excessively high levels of epitope are attained. J Immunol. 1999; 163(7):3735-45. View

15.

Slingluff Jr C, Petroni G, Yamshchikov G, Hibbitts S, Grosh W, Chianese-Bullock K . Immunologic and clinical outcomes of vaccination with a multiepitope melanoma peptide vaccine plus low-dose interleukin-2 administered either concurrently or on a delayed schedule. J Clin Oncol. 2004; 22(22):4474-85. DOI: 10.1200/JCO.2004.10.212. View

16.

Speiser D, Lienard D, Rufer N, Rubio-Godoy V, Rimoldi D, Lejeune F . Rapid and strong human CD8+ T cell responses to vaccination with peptide, IFA, and CpG oligodeoxynucleotide 7909. J Clin Invest. 2005; 115(3):739-46. PMC: 546459. DOI: 10.1172/JCI23373. View

17.

Melchionda F, Fry T, Milliron M, McKirdy M, Tagaya Y, Mackall C . Adjuvant IL-7 or IL-15 overcomes immunodominance and improves survival of the CD8+ memory cell pool. J Clin Invest. 2005; 115(5):1177-87. PMC: 1074679. DOI: 10.1172/JCI23134. View

18.

Bachmann M, Wolint P, Schwarz K, Jager P, Oxenius A . Functional properties and lineage relationship of CD8+ T cell subsets identified by expression of IL-7 receptor alpha and CD62L. J Immunol. 2005; 175(7):4686-96. DOI: 10.4049/jimmunol.175.7.4686. View

19.

Kochenderfer J, Chien C, Simpson J, Gress R . Synergism between CpG-containing oligodeoxynucleotides and IL-2 causes dramatic enhancement of vaccine-elicited CD8+ T cell responses. J Immunol. 2006; 177(12):8860-73. DOI: 10.4049/jimmunol.177.12.8860. View

20.

Kochenderfer J, Simpson J, Chien C, Gress R . Vaccination regimens incorporating CpG-containing oligodeoxynucleotides and IL-2 generate antigen-specific antitumor immunity from T-cell populations undergoing homeostatic peripheral expansion after BMT. Blood. 2007; 110(1):450-60. PMC: 1896127. DOI: 10.1182/blood-2006-11-057935. View